-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Py3JyrzDcrr/7q4Y/uWj8KpCowXCKfAVc8GX1+uIAqotS3Ph6mPM9vYQvjTlNW+d najpULN2aJ1EHrGXNC5KWQ== 0001104659-05-062999.txt : 20051229 0001104659-05-062999.hdr.sgml : 20051229 20051229113108 ACCESSION NUMBER: 0001104659-05-062999 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20051228 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events FILED AS OF DATE: 20051229 DATE AS OF CHANGE: 20051229 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIPID SCIENCES INC/ CENTRAL INDEX KEY: 0000071478 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 430433090 STATE OF INCORPORATION: AZ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-00497 FILM NUMBER: 051290368 BUSINESS ADDRESS: STREET 1: 7068 KOLL CENTER PARKWAY STREET 2: SUITE 401 CITY: PLEASANTON STATE: CA ZIP: 94566 BUSINESS PHONE: 925-249-4000 MAIL ADDRESS: STREET 1: 7068 KOLL CENTER PARKWAY STREET 2: SUITE 401 CITY: PLEASANTON STATE: CA ZIP: 94566 FORMER COMPANY: FORMER CONFORMED NAME: NZ CORP DATE OF NAME CHANGE: 20000810 FORMER COMPANY: FORMER CONFORMED NAME: NEW MEXICO & ARIZONA LAND CO DATE OF NAME CHANGE: 19920703 8-K 1 a05-22524_18k.htm CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  December 28, 2005

 

LIPID SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-497

 

43-0433090

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(I.R.S Employer Identification No.)

 

 

 

 

 

7068 Koll Center Parkway, Suite 401, Pleasanton, California

 

94566

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:  (925) 249-4000

 

(Former name or former address, if changed since last report.)  N/A

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 1.01 Entry into a Material Definitive Agreement.

 

On December 28, 2005, Lipid Sciences, Inc. (the “Corporation”) entered into a Separation Agreement and Release with Marc Bellotti, effective as of December 31, 2005, in connection with Mr. Bellotti’s resignation from his position as Vice President of Research and Development of the Corporation.  In consideration for a general release of claims, (1) Mr. Bellotti’s stock option granted on July 2, 2001 covering 155,902 shares of the Corporation’s common stock will be amended so that the stock option may be exercised until December 31, 2006 (such stock option previously would have expired three months following Mr. Bellotti’s resignation) and (2) Mr. Bellotti’s stock option granted on March 14, 2003 covering 160,000 shares of the Corporation’s common stock will be amended so that the stock option is immediately fully exercisable as to all of the shares (such stock option previously would have become fully vested as to the remaining 40,000 unvested shares on March 14, 2006).  In addition, Mr. Bellotti was offered the opportunity to serve as a consultant in accordance with the terms of a consulting agreement, as described in Item 8.01 below.

 

Item 8.01 Other Events.

 

On December 28, 2005, Marc Bellotti resigned from his position as Vice President of Research and Development of the Corporation, effective December 31, 2005.  Mr. Bellotti will continue to provide consulting services to the Corporation pursuant to a consulting agreement between the Corporation and Mr. Bellotti, effective as of January 1, 2006.  The consulting agreement provides that Mr. Bellotti will continue to assist on projects he was working on prior to his December 31, 2005 resignation.  His services will be under the direction of the Corporation’s Chief Executive Officer.  Mr. Bellotti will be compensated on a per diem basis if he provides services at the Corporation’s offices and on an hourly basis for telephonic meetings.  The consulting agreement generally expires on December 31, 2006.

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Lipid Sciences, Inc.

 

 

 

 

 

 

 

 

 

 

Date: December 29, 2005

 

By:

/s/ Sandra Gardiner

 

 

 

Name:

Sandra Gardiner

 

 

Title:

Chief Financial Officer

 

3

 -----END PRIVACY-ENHANCED MESSAGE-----